Launch of the Accelerating Medicines Partnership for Common Metabolic Diseases

We are proud to announce our participation in a new collaborative effort launched today: the Accelerating Medicines Partnership for Common Metabolic Diseases (AMP-CMD), building on the foundation of the AMP-T2D consortium and the AMP-T2D Knowledge Portal. This public-private partnership includes the Foundation for the National Institutes of Health (FNIH), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), pharmaceutical partners at Amgen, Eli Lilly and Company, Novo Nordisk, and Pfizer Inc. AMP-CMD funds research into the molecular basis of common diseases such as diabetes, cardiovascular disease, obesity, and kidney and liver disease at many institutions, and also supports the AMP-CMD Knowledge Portal to represent these research results. Find more details in a press release from the FNIH.

With today's launch, we also have a new release of data and features to the CMDKP: 20 new datasets and 25 additional traits, adding associations for a whole range of diabetic complications and a variety of other cardiometabolic phenotypes. Look for news items describing the updates in the next few days!

md, t1d, t2d, cd, cvd, sleep